FBXO8 and asthma: It has been reported previously that DC10 treatments reverse the disease phenotype in OVA and house dust mite models of asthma, wherein they suppress the allergen-specific T cell response [7,8,9,16], inducing Th2 cells to differentiate into CD4+CD25+Foxp3+ Treg [14].